Disposition of 110447 shares by Thomas Watkins of Horizon Pharma subject to Rule 16b-3
| FRBRX Fund | USD 147.44 1.08 0.74% |
Slightly above 53% of Franklin Biotechnology's investor base is interested to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are impartial at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
Filed transaction by Horizon Therapeutics Publ director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Franklin Biotechnology is currently under evaluation in probability of bankruptcy among similar funds. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| TEBIX | Franklin Mutual | 0.53 |
| ||
| TEDSX | Franklin Mutual | 0.54 |
| ||
| TEDRX | Franklin Mutual | 0.55 |
| ||
| TEGBX | Templeton Global | 0.59 |
| ||
| TEGRX | Templeton Growth | 0.64 |
| ||
| TEFRX | Templeton Foreign | 0.64 |
| ||
| TEDIX | Franklin Mutual | 0.64 |
| ||
| TEMFX | Templeton Foreign | 0.75 |
| ||
| TEDMX | Templeton Developing | 0.91 |
| ||
| TEFTX | Templeton Foreign | 1.11 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |